---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-021093"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-06-24T23:59:59+00:00"
generated_at: "2026-05-18T22:34:01.963872+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Genprex reports positive preclinical data for diabetes gene therapy GPX-002 at ADA

## Summary
- Alpha cells in Type 1 diabetes mouse models transdifferentiated to insulin-secreting beta-like cells after GPX-002 infusion.
- In diabetic non-human primates, GPX-002 improved glucose tolerance and reduced insulin requirements at one month post-infusion.
- Three-month immunosuppression with rituximab, rapamycin, and steroids largely prevented anti-viral immunity in NHPs.
- Continued studies will evaluate GPX-002 efficacy after six months of immunosuppression in NHP models.

## SEC filing metadata
- accession: 0001437749-25-021093
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925021093/0001437749-25-021093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925021093/gnpx20250618c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-021093
- JSON: https://secwatch.observer/filing/0001437749-25-021093.json
- Plain text: https://secwatch.observer/filing/0001437749-25-021093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.